Loading…

Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load

Preventing hepatitis B by vaccination is essential in HIV-infected patients (higher progression rate of HBV infection to chronicity, lower rate of serum HBe Ag loss). However, it has been shown a decreased anti-HBs response in these individuals after a standard vaccination (3 doses of 20 μg). Thus,...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2000-01, Vol.18 (13), p.1161-1165
Main Authors: Rey, David, Krantz, Véronique, Partisani, Marialuisa, Schmitt, Marie-Paule, Meyer, Pierre, Libbrecht, Eric, Wendling, Marie-Josée, Vetter, Denis, Nicolle, Margreet, Kempf-Durepaire, Georgette, Lang, Jean-Marie
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c539t-9a9413ffa4a5bdef62eb562503b420ab97e275b4104ed886204ecefce5ea33333
cites cdi_FETCH-LOGICAL-c539t-9a9413ffa4a5bdef62eb562503b420ab97e275b4104ed886204ecefce5ea33333
container_end_page 1165
container_issue 13
container_start_page 1161
container_title Vaccine
container_volume 18
creator Rey, David
Krantz, Véronique
Partisani, Marialuisa
Schmitt, Marie-Paule
Meyer, Pierre
Libbrecht, Eric
Wendling, Marie-Josée
Vetter, Denis
Nicolle, Margreet
Kempf-Durepaire, Georgette
Lang, Jean-Marie
description Preventing hepatitis B by vaccination is essential in HIV-infected patients (higher progression rate of HBV infection to chronicity, lower rate of serum HBe Ag loss). However, it has been shown a decreased anti-HBs response in these individuals after a standard vaccination (3 doses of 20 μg). Thus, we tested the hypothesis that doubling the number of hepatitis B vaccine injections might increase anti-HBs response rate. HIV-infected patients with CD4 >200/μl, who were on stable antiretroviral treatment, as well as seronegative for HBV markers, and who have never been vaccinated against HBV, were given 3 intramuscular injections of Genhevac B 20 μg at 1 month intervals. Initial non responders were given 3 additional monthly injections. Anti-HBs titer was followed. We also evaluated the effects on HIV-1 viral load. Twenty patients with a median CD4 cell count of 470/μl were enrolled. The response rate after three 20 μg injections was 55% (11/20), lower in individuals with CD4 between 200 and 500/μl (4/12=33.3%), compared to patients with CD4 above 500/μl (7/8=87.5%, P=0.02). Among 9 initial non-responders, only 2 did not respond to 3 additional doses; thus, the overall response rate was 90% (18/20). Geometric mean titers of anti-HBs were 133 IU/l and 77.5 IU/l, after 3 and 6 Genhevac doses, respectively ( P=0.38). One year later, only 10/17 (58.8%) patients had protective anti-HBs. Five patients experienced a significant viral load increase, transient in 3 cases. These preliminary results suggest that doubling the number of hepatitis B vaccinations in HIV-infected patients might significantly improve anti-HBs response rate; however, close monitoring of anti-HBs is necessary because of its short-lived persistence. The effects on HIV-1 viral load are limited.
doi_str_mv 10.1016/S0264-410X(99)00389-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70865288</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X99003898</els_id><sourcerecordid>17453156</sourcerecordid><originalsourceid>FETCH-LOGICAL-c539t-9a9413ffa4a5bdef62eb562503b420ab97e275b4104ed886204ecefce5ea33333</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhJ4B8QKgcUvwRO_EJ0ap0V6rUAx_iZjnOuHWVOFs7WYkf0f-Ms1mV3urLWJ5nZjzvi9B7Sk4pofLLD8JkWZSU_DlR6jMhvFZF_QKtaF3xgglav0SrR-QIvUnpjhAiOFWv0RElslSSyhV62AQbwSQfbvB4CzhMfQMRDw7fwtaMfvQJn-GdsdYHwD7cgR39EBI2000PYcyXMPpifZZwhLTNGcDRjDOK15vfhQ8uV0CL52Yzf4ov3PyU8LAQFO98NB3uBtO-Ra-c6RK8O8Rj9Ov7xc_zdXF1fbk5_3ZVWMHVWCijSsqdM6URTQtOMmiEZILwpmTENKoCVokmb15CW9eS5WjBWRBg-HyO0ael7zYO9xOkUfc-Weg6E2CYkq5ILQWr62dBWpVZUiEzKBbQxiGlCE5vo-9N_Ksp0bNhem-Ynt3QSum9YXoe8OEwYGp6aJ9ULQ5l4OMBMMmazkUTrE__OSY532NfFwyybDsPUSeb9bbQ-pjV1u3gn_nJP0Pss0Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17453156</pqid></control><display><type>article</type><title>Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Rey, David ; Krantz, Véronique ; Partisani, Marialuisa ; Schmitt, Marie-Paule ; Meyer, Pierre ; Libbrecht, Eric ; Wendling, Marie-Josée ; Vetter, Denis ; Nicolle, Margreet ; Kempf-Durepaire, Georgette ; Lang, Jean-Marie</creator><creatorcontrib>Rey, David ; Krantz, Véronique ; Partisani, Marialuisa ; Schmitt, Marie-Paule ; Meyer, Pierre ; Libbrecht, Eric ; Wendling, Marie-Josée ; Vetter, Denis ; Nicolle, Margreet ; Kempf-Durepaire, Georgette ; Lang, Jean-Marie</creatorcontrib><description>Preventing hepatitis B by vaccination is essential in HIV-infected patients (higher progression rate of HBV infection to chronicity, lower rate of serum HBe Ag loss). However, it has been shown a decreased anti-HBs response in these individuals after a standard vaccination (3 doses of 20 μg). Thus, we tested the hypothesis that doubling the number of hepatitis B vaccine injections might increase anti-HBs response rate. HIV-infected patients with CD4 &gt;200/μl, who were on stable antiretroviral treatment, as well as seronegative for HBV markers, and who have never been vaccinated against HBV, were given 3 intramuscular injections of Genhevac B 20 μg at 1 month intervals. Initial non responders were given 3 additional monthly injections. Anti-HBs titer was followed. We also evaluated the effects on HIV-1 viral load. Twenty patients with a median CD4 cell count of 470/μl were enrolled. The response rate after three 20 μg injections was 55% (11/20), lower in individuals with CD4 between 200 and 500/μl (4/12=33.3%), compared to patients with CD4 above 500/μl (7/8=87.5%, P=0.02). Among 9 initial non-responders, only 2 did not respond to 3 additional doses; thus, the overall response rate was 90% (18/20). Geometric mean titers of anti-HBs were 133 IU/l and 77.5 IU/l, after 3 and 6 Genhevac doses, respectively ( P=0.38). One year later, only 10/17 (58.8%) patients had protective anti-HBs. Five patients experienced a significant viral load increase, transient in 3 cases. These preliminary results suggest that doubling the number of hepatitis B vaccinations in HIV-infected patients might significantly improve anti-HBs response rate; however, close monitoring of anti-HBs is necessary because of its short-lived persistence. The effects on HIV-1 viral load are limited.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(99)00389-8</identifier><identifier>PMID: 10649616</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; AIDS/HIV ; Animals ; Anti-HBs ; Biological and medical sciences ; CD4 Lymphocyte Count ; CD4 T lymphocyte count ; CHO Cells ; Cricetinae ; Epidemiology. Vaccinations ; Female ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; General aspects ; Hepatitis B - blood ; Hepatitis B - prevention &amp; control ; Hepatitis B - virology ; Hepatitis B Antibodies - biosynthesis ; Hepatitis B Antibodies - blood ; Hepatitis B Antibodies - immunology ; Hepatitis B Surface Antigens - blood ; Hepatitis B Surface Antigens - immunology ; Hepatitis B vaccination ; Hepatitis B Vaccines - administration &amp; dosage ; HIV Infections - blood ; HIV Infections - immunology ; HIV Infections - virology ; HIV-1 ; HIV-1 viral load ; Human immunodeficiency virus 1 ; Humans ; Immunization Schedule ; Infectious diseases ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Prospective Studies ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Viral Load ; Virology</subject><ispartof>Vaccine, 2000-01, Vol.18 (13), p.1161-1165</ispartof><rights>2000 Elsevier Science Ltd</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c539t-9a9413ffa4a5bdef62eb562503b420ab97e275b4104ed886204ecefce5ea33333</citedby><cites>FETCH-LOGICAL-c539t-9a9413ffa4a5bdef62eb562503b420ab97e275b4104ed886204ecefce5ea33333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1263316$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10649616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rey, David</creatorcontrib><creatorcontrib>Krantz, Véronique</creatorcontrib><creatorcontrib>Partisani, Marialuisa</creatorcontrib><creatorcontrib>Schmitt, Marie-Paule</creatorcontrib><creatorcontrib>Meyer, Pierre</creatorcontrib><creatorcontrib>Libbrecht, Eric</creatorcontrib><creatorcontrib>Wendling, Marie-Josée</creatorcontrib><creatorcontrib>Vetter, Denis</creatorcontrib><creatorcontrib>Nicolle, Margreet</creatorcontrib><creatorcontrib>Kempf-Durepaire, Georgette</creatorcontrib><creatorcontrib>Lang, Jean-Marie</creatorcontrib><title>Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Preventing hepatitis B by vaccination is essential in HIV-infected patients (higher progression rate of HBV infection to chronicity, lower rate of serum HBe Ag loss). However, it has been shown a decreased anti-HBs response in these individuals after a standard vaccination (3 doses of 20 μg). Thus, we tested the hypothesis that doubling the number of hepatitis B vaccine injections might increase anti-HBs response rate. HIV-infected patients with CD4 &gt;200/μl, who were on stable antiretroviral treatment, as well as seronegative for HBV markers, and who have never been vaccinated against HBV, were given 3 intramuscular injections of Genhevac B 20 μg at 1 month intervals. Initial non responders were given 3 additional monthly injections. Anti-HBs titer was followed. We also evaluated the effects on HIV-1 viral load. Twenty patients with a median CD4 cell count of 470/μl were enrolled. The response rate after three 20 μg injections was 55% (11/20), lower in individuals with CD4 between 200 and 500/μl (4/12=33.3%), compared to patients with CD4 above 500/μl (7/8=87.5%, P=0.02). Among 9 initial non-responders, only 2 did not respond to 3 additional doses; thus, the overall response rate was 90% (18/20). Geometric mean titers of anti-HBs were 133 IU/l and 77.5 IU/l, after 3 and 6 Genhevac doses, respectively ( P=0.38). One year later, only 10/17 (58.8%) patients had protective anti-HBs. Five patients experienced a significant viral load increase, transient in 3 cases. These preliminary results suggest that doubling the number of hepatitis B vaccinations in HIV-infected patients might significantly improve anti-HBs response rate; however, close monitoring of anti-HBs is necessary because of its short-lived persistence. The effects on HIV-1 viral load are limited.</description><subject>Adult</subject><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Anti-HBs</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>CD4 T lymphocyte count</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Epidemiology. Vaccinations</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General aspects</subject><subject>Hepatitis B - blood</subject><subject>Hepatitis B - prevention &amp; control</subject><subject>Hepatitis B - virology</subject><subject>Hepatitis B Antibodies - biosynthesis</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B Antibodies - immunology</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B Surface Antigens - immunology</subject><subject>Hepatitis B vaccination</subject><subject>Hepatitis B Vaccines - administration &amp; dosage</subject><subject>HIV Infections - blood</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - virology</subject><subject>HIV-1</subject><subject>HIV-1 viral load</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>Immunization Schedule</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Viral Load</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFkU1v1DAQhi0EokvhJ4B8QKgcUvwRO_EJ0ap0V6rUAx_iZjnOuHWVOFs7WYkf0f-Ms1mV3urLWJ5nZjzvi9B7Sk4pofLLD8JkWZSU_DlR6jMhvFZF_QKtaF3xgglav0SrR-QIvUnpjhAiOFWv0RElslSSyhV62AQbwSQfbvB4CzhMfQMRDw7fwtaMfvQJn-GdsdYHwD7cgR39EBI2000PYcyXMPpifZZwhLTNGcDRjDOK15vfhQ8uV0CL52Yzf4ov3PyU8LAQFO98NB3uBtO-Ra-c6RK8O8Rj9Ov7xc_zdXF1fbk5_3ZVWMHVWCijSsqdM6URTQtOMmiEZILwpmTENKoCVokmb15CW9eS5WjBWRBg-HyO0ael7zYO9xOkUfc-Weg6E2CYkq5ILQWr62dBWpVZUiEzKBbQxiGlCE5vo-9N_Ksp0bNhem-Ynt3QSum9YXoe8OEwYGp6aJ9ULQ5l4OMBMMmazkUTrE__OSY532NfFwyybDsPUSeb9bbQ-pjV1u3gn_nJP0Pss0Y</recordid><startdate>20000118</startdate><enddate>20000118</enddate><creator>Rey, David</creator><creator>Krantz, Véronique</creator><creator>Partisani, Marialuisa</creator><creator>Schmitt, Marie-Paule</creator><creator>Meyer, Pierre</creator><creator>Libbrecht, Eric</creator><creator>Wendling, Marie-Josée</creator><creator>Vetter, Denis</creator><creator>Nicolle, Margreet</creator><creator>Kempf-Durepaire, Georgette</creator><creator>Lang, Jean-Marie</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20000118</creationdate><title>Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load</title><author>Rey, David ; Krantz, Véronique ; Partisani, Marialuisa ; Schmitt, Marie-Paule ; Meyer, Pierre ; Libbrecht, Eric ; Wendling, Marie-Josée ; Vetter, Denis ; Nicolle, Margreet ; Kempf-Durepaire, Georgette ; Lang, Jean-Marie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c539t-9a9413ffa4a5bdef62eb562503b420ab97e275b4104ed886204ecefce5ea33333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Anti-HBs</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>CD4 T lymphocyte count</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Epidemiology. Vaccinations</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General aspects</topic><topic>Hepatitis B - blood</topic><topic>Hepatitis B - prevention &amp; control</topic><topic>Hepatitis B - virology</topic><topic>Hepatitis B Antibodies - biosynthesis</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B Antibodies - immunology</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B Surface Antigens - immunology</topic><topic>Hepatitis B vaccination</topic><topic>Hepatitis B Vaccines - administration &amp; dosage</topic><topic>HIV Infections - blood</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - virology</topic><topic>HIV-1</topic><topic>HIV-1 viral load</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>Immunization Schedule</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Viral Load</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rey, David</creatorcontrib><creatorcontrib>Krantz, Véronique</creatorcontrib><creatorcontrib>Partisani, Marialuisa</creatorcontrib><creatorcontrib>Schmitt, Marie-Paule</creatorcontrib><creatorcontrib>Meyer, Pierre</creatorcontrib><creatorcontrib>Libbrecht, Eric</creatorcontrib><creatorcontrib>Wendling, Marie-Josée</creatorcontrib><creatorcontrib>Vetter, Denis</creatorcontrib><creatorcontrib>Nicolle, Margreet</creatorcontrib><creatorcontrib>Kempf-Durepaire, Georgette</creatorcontrib><creatorcontrib>Lang, Jean-Marie</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rey, David</au><au>Krantz, Véronique</au><au>Partisani, Marialuisa</au><au>Schmitt, Marie-Paule</au><au>Meyer, Pierre</au><au>Libbrecht, Eric</au><au>Wendling, Marie-Josée</au><au>Vetter, Denis</au><au>Nicolle, Margreet</au><au>Kempf-Durepaire, Georgette</au><au>Lang, Jean-Marie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2000-01-18</date><risdate>2000</risdate><volume>18</volume><issue>13</issue><spage>1161</spage><epage>1165</epage><pages>1161-1165</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Preventing hepatitis B by vaccination is essential in HIV-infected patients (higher progression rate of HBV infection to chronicity, lower rate of serum HBe Ag loss). However, it has been shown a decreased anti-HBs response in these individuals after a standard vaccination (3 doses of 20 μg). Thus, we tested the hypothesis that doubling the number of hepatitis B vaccine injections might increase anti-HBs response rate. HIV-infected patients with CD4 &gt;200/μl, who were on stable antiretroviral treatment, as well as seronegative for HBV markers, and who have never been vaccinated against HBV, were given 3 intramuscular injections of Genhevac B 20 μg at 1 month intervals. Initial non responders were given 3 additional monthly injections. Anti-HBs titer was followed. We also evaluated the effects on HIV-1 viral load. Twenty patients with a median CD4 cell count of 470/μl were enrolled. The response rate after three 20 μg injections was 55% (11/20), lower in individuals with CD4 between 200 and 500/μl (4/12=33.3%), compared to patients with CD4 above 500/μl (7/8=87.5%, P=0.02). Among 9 initial non-responders, only 2 did not respond to 3 additional doses; thus, the overall response rate was 90% (18/20). Geometric mean titers of anti-HBs were 133 IU/l and 77.5 IU/l, after 3 and 6 Genhevac doses, respectively ( P=0.38). One year later, only 10/17 (58.8%) patients had protective anti-HBs. Five patients experienced a significant viral load increase, transient in 3 cases. These preliminary results suggest that doubling the number of hepatitis B vaccinations in HIV-infected patients might significantly improve anti-HBs response rate; however, close monitoring of anti-HBs is necessary because of its short-lived persistence. The effects on HIV-1 viral load are limited.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10649616</pmid><doi>10.1016/S0264-410X(99)00389-8</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2000-01, Vol.18 (13), p.1161-1165
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_70865288
source ScienceDirect Freedom Collection 2022-2024
subjects Adult
AIDS/HIV
Animals
Anti-HBs
Biological and medical sciences
CD4 Lymphocyte Count
CD4 T lymphocyte count
CHO Cells
Cricetinae
Epidemiology. Vaccinations
Female
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
General aspects
Hepatitis B - blood
Hepatitis B - prevention & control
Hepatitis B - virology
Hepatitis B Antibodies - biosynthesis
Hepatitis B Antibodies - blood
Hepatitis B Antibodies - immunology
Hepatitis B Surface Antigens - blood
Hepatitis B Surface Antigens - immunology
Hepatitis B vaccination
Hepatitis B Vaccines - administration & dosage
HIV Infections - blood
HIV Infections - immunology
HIV Infections - virology
HIV-1
HIV-1 viral load
Human immunodeficiency virus 1
Humans
Immunization Schedule
Infectious diseases
Male
Medical sciences
Microbiology
Middle Aged
Prospective Studies
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Viral Load
Virology
title Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A33%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increasing%20the%20number%20of%20hepatitis%20B%20vaccine%20injections%20augments%20anti-HBs%20response%20rate%20in%20HIV-infected%20patients.%20Effects%20on%20HIV-1%20viral%20load&rft.jtitle=Vaccine&rft.au=Rey,%20David&rft.date=2000-01-18&rft.volume=18&rft.issue=13&rft.spage=1161&rft.epage=1165&rft.pages=1161-1165&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(99)00389-8&rft_dat=%3Cproquest_cross%3E17453156%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c539t-9a9413ffa4a5bdef62eb562503b420ab97e275b4104ed886204ecefce5ea33333%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17453156&rft_id=info:pmid/10649616&rfr_iscdi=true